‘Cracks Show’ as CDRH Staff Contend with Heavy Workloads

Why It Matters

The staffing crisis threatens the FDA’s ability to ensure device safety and could delay market entry for med‑tech firms, reshaping industry timelines and patient access. Regulators and manufacturers alike face heightened uncertainty as the agency struggles to maintain review quality.

Key Takeaways

• FDA lost over 4,400 employees (21%) 2024‑2026
• CDRH workload surged, morale plummeted
• Device approvals remained on target despite staffing cuts
• Hiring freeze lifted, but recruitment will take years
• Industry faces delayed feedback and inconsistent guidance

Pulse Analysis

The wave of reductions that began in early 2024 under the Trump administration reshaped the Department of Health and Human Services, with the FDA’s device center bearing a disproportionate share of the cuts. By stripping away hundreds of probationary staff and senior reviewers, the agency lost institutional memory and a pipeline of talent that traditionally underpins rigorous pre‑market evaluation. This contraction coincided with a broader push to streamline regulatory processes, yet the abrupt loss of expertise has left the CDRH scrambling to meet statutory deadlines while preserving safety standards.

Operational strain is now evident across the CDRH’s workflow. Reviewers report heavier case loads, rushed deficiency letters, and last‑minute labeling changes that force sponsors into costly redesigns. The inconsistency in feedback—sometimes shifting mid‑review—has eroded confidence among med‑tech firms, prompting concerns about delayed product launches and increased compliance risk. Moreover, the morale dip among remaining staff raises the specter of burnout, which could compromise post‑market surveillance activities such as inspections and recall management, essential components of patient safety.

While the federal hiring freeze has been lifted and the FDA announced plans to recruit more than 1,000 reviewers and inspectors, rebuilding the lost capacity will be a multi‑year effort. Training new reviewers typically requires two to three years, meaning the agency will operate with a talent gap well into the mid‑2020s. Policymakers may need to consider targeted funding, retention incentives, and clearer staffing metrics to prevent future attrition. For industry stakeholders, proactive engagement with the FDA and contingency planning for longer review cycles will be critical to navigating this period of regulatory turbulence.